Last reviewed · How we verify

gemcitabine/carboplatin plus Iniparib — Competitive Intelligence Brief

gemcitabine/carboplatin plus Iniparib (gemcitabine/carboplatin plus Iniparib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy. Area: Oncology.

phase 3 chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

gemcitabine/carboplatin plus Iniparib (gemcitabine/carboplatin plus Iniparib) — Sanofi. Gemcitabine and carboplatin work by interfering with DNA replication and cell division, respectively, while iniparib is thought to work by inhibiting PARP enzymes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
gemcitabine/carboplatin plus Iniparib TARGET gemcitabine/carboplatin plus Iniparib Sanofi phase 3 chemotherapy
Eloxatin Oxaliplatin Yakult Honsha marketed Platinum-based chemotherapy agent DNA 2002-01-01
PUVA (8MOP + UVA) + IFN PUVA (8MOP + UVA) + IFN Madrilenian Group of Cutaneous Lymphomas marketed Photochemotherapy + cytokine combination
Oxaliplatin (OXAL) Oxaliplatin (OXAL) Memorial Sloan Kettering Cancer Center marketed Platinum-based chemotherapy agent DNA
irinotecan + Carboplatin + erbitux irinotecan-carboplatin-erbitux Pfizer marketed chemotherapy topoisomerase I, platinum DNA damage, epidermal growth factor receptor
aflibercept + FOLFIRI aflibercept + FOLFIRI CR-CSSS Champlain-Charles-Le Moyne marketed VEGF inhibitor (fusion protein) + chemotherapy combination VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component)
DSP DSP Taiwan Liposome Company marketed Liposomal anthracycline chemotherapy Topoisomerase II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy class)

  1. Pfizer · 3 drugs in this class
  2. Chengdu New Radiomedicine Technology Co. LTD. · 1 drug in this class
  3. Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
  4. Chinese Society of Lung Cancer · 1 drug in this class
  5. Hutchmed · 1 drug in this class
  6. Prof. Massimo Aglietta · 1 drug in this class
  7. Sanofi · 1 drug in this class
  8. Sun Yat-sen University · 1 drug in this class
  9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  10. Swiss Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). gemcitabine/carboplatin plus Iniparib — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-carboplatin-plus-iniparib. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: